Well-funded biotech Intarcia Therapeutics is rolling along with its ambitious plans to develop a diabetes treatment without Big Pharma's help, posting positive results from two late-stage studies on its once-a-year drug-device combo.
Eli Lilly's tabalumab has flopped in another Phase III program, failing to score well enough to survive as a potential new treatment for lupus--a follow-up setback to its earlier failure in rheumatoid arthritis. Lilly now plans to bury the program in its crowded graveyard of late-stage drugs.
A novel treatment made by tiny Mapp Biopharmaceutical may be the key to beating back West Africa's Ebola outbreak, but despite the support of the U.S. government and some of the world's largest charities, producing enough to counter the spread will be difficult.
Esperion Therapeutics has taken another big stride along the clinical path for its cholesterol drug. The biotech reports that its drug ETC-1002 slashed levels of the bad cholesterol LDL, particularly when it was combined with Merck's Zetia, in a Phase IIb trial. And now that the mid-stage program is complete, the Ann Arbor, MI-based biotech finds itself at the threshold of a late-stage program with a drug the company feels can thread the market needle between cheap generics and a looming wave of rival biologics.
Backed by the insights of a high-profile MIT scientist with a lead antibody now poised to make an assault on a Phase II proof-of-concept study, Visterra has rounded up a $30 million venture round for its next-gen work on infectious diseases from a marquee group of investors and now plans to beef up the pipeline.
Allergan has signed a lease for big chunk of office space in Texas, according to the Austin Business Journal, keeping quiet on its plans as it slashes jobs around the globe.
European venture outfit LSP (Life Sciences Partners) has raised $100 million toward a new biotech fund, setting out to stake a dozen or so innovators in drugs, devices and diagnostics.
French pharma giant Sanofi has unveiled plans to bring together the drug development work being done in a dozen different Pacific Rim countries, creating a major new R&D center in Shanghai that will employ 1,400 staffers.
Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.
Flush with cash from its high-profile collaborators, FibroGen is plotting a $120 million IPO to help bankroll a stable of unpartnered drugs, including a promising lung treatment with huge market potential.
According to the biotech Enanta, you can count Novartis out of the race to develop next-gen hepatitis C cocktails. The pharma giant has bowed out of its partnership with Enanta on an NS5A inhibitor code-named EDP-239, which attracted a $440 million deal--including $36 million upfront--back in 2012.
Fresh off an IPO, Ardelyx reports that its lead drug tenapanor (RDX5791) scored a success in a large Phase IIb trial for irritable bowel syndrome. And that counts as a win for AstraZeneca, which signed a $272 million partnership deal on the drug back in 2012--part of a deal frenzy aimed at repairing a damaged pipeline.
GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.
Four months after it signed an option pact that included $33 million in an upfront and early milestone, along with $468 million in add-on incentives, Takeda has agreed to pay the freight on researching up to four more MacroGenics programs while adding up to $400 million each--$1.6 billion in total--in fresh milestones.
Chicago-based Baxter International has inked a 200,000-square-foot lease in the heart of Cambridge, MA's biotech hub which will become the new research center of its soon-to-be-spun-out biopharma division, Baxalta.
Catalyst Pharmaceutical Partners is heralding positive late-stage results for its lead drug, planning to make its case to the FDA in hopes of winning approval for a much-scrutinized orphan treatment.
The U.K.'s Horizon Discovery has snapped up St. Louis-based Sage Labs for $48 million in cash and stock.
Thomson Reuters BioWorld took a deep dive into the subject and surfaced today with a detailed report outlining a bustling new global business with roughly 700 so-called follow-ons put in the clinic by 245 companies and institutions. Looking ahead to 2020, analysts say, you can anticipate that biosimilars will account for about $25 billion out of $100 billion in sales for off-patent biologics.